Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Xiangyu Yan, Songhan Huang, Yang Yang, Ziwen Lu, Feiyu Li, Liyong Jiang, Yong Jiang, Jun Liu – 15 December 2021 – The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVL]) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research. Therefore, we performed this systematic review and meta‐analysis to investigate the potential survival benefits of mTOR inhibitors (mTORis).

Low Levels of Hepatocyte‐Specific Methylation in Cell‐Free DNA Are a Strong Negative Predictor for Acute T Cell–Mediated Rejection Requiring Treatment Following Liver Transplantation

Daniel R. A. Cox, Nicholas Low, Su Kah Goh, Eunice Lee, Angela Vago, Louise Jackett, Julie Lokan, Sabine Braat, Robert Jones, Adam Testro, Alexander Dobrovic, Vijayaragavan Muralidharan – 15 December 2021 – Graft‐derived cell‐free DNA (gdcfDNA) quantification is a promising, minimally invasive tool for detecting acute T cell–mediated rejection (ATCMR) following liver transplantation (LT). We investigated the utility of measuring hepatocyte‐specific methylation in cfDNA (HS‐cfDNA) to quantify gdcfDNA, examining its accuracy in detecting ATCMR in a prospective, cross‐sectional study.

Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study

Chun‐Yan Wang, Ya Deng, Ping Li, Sujun Zheng, Guofeng Chen, Guangde Zhou, Jing Xu, Yan‐Ping Chen, Zheng Wang, Xueyuan Jin, Jin‐Mo Tang, Kun‐Peng Hu, Jing‐Feng Bi, Ping Zhang, Chun‐Xia Li, Ang Huang, Gui‐Ji Lv, Xiao‐He Xiao, Zhengsheng Zou, Dong Ji – 15 December 2021

Adverse Effects of Anti‐Covid‐19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes

Atousa Khalatbari, Zahra Aghazadeh, Cheng Ji – 14 December 2021 – During the pandemic, dexamethasone (DEX), remdesivir (RDV), hydroxychloroquine (HCQ), thapsigargin (TG), camostat mesylate (CaM), and pralatrexate were repurposed drugs for coronavirus disease 2019 (COVID‐19). However, the side effects on the liver associated with the anti‐COVID therapies are unknown. Cellular stresses by these drugs at 0‐30 μM were studied using HepG2, Huh7, and/or primary human hepatocytes.

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis

Thomas Reiberger – 13 December 2021 – Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents.

Subscribe to